Construction & Building Materials

LafargeHolcim

Price CHF44.84

Reuters 12-month High / Market Cap (CHF Ev (BG Estimates Avg. 6m daily vo 3y EPS CAGR	HOLN VX HOLZn.VX 72.9 / 44.8 27,214 45,750 1,893 30.4%			
	1 M	3 M	6 M 3	1/12/14
Absolute perf.	-10.0%	-20.5%	-35.7%	-37.2%
Cons & Mat	-4.1%	-2.9%	-6.9%	8.9%
DJ Stoxx 600	-4.4%	-6.2%	-12.5%	-0.7%
YEnd Dec. (EURm)	2014	2015 e	2016e	2017 e
Sales	31,564	29,968	31,571	33,640
% change		-5.1%	5.3%	6.6%
EBITDA	6,495	5,899	6,751	7,907
EBIT	3,765	3,273	4,111	5,268
% change		-13.1%	25.6%	28.1%
Net income	1,247	1,249	1,983	2,769
% change		0.1%	58.8%	39.6%
	2014	2015e	2016e	2017e
Operating margin	11.9	10.9	13.0	15.7
Net margin	5.3	3.8	5.6	8.6
ROE	3.3	3.3	5.2	6.9
ROCE	3.4	3.8	4.7	6.1
Gearing	41.6	39.9	37.0	31.0
(EUR)	2014	2015e	2016 e	2017 e
EPS	2.06	2.06	3.27	4.57
% change	-	0.1%	58.8%	39.6%
P/E	21.8x	21.7x	13.7x	9.8x
FCF yield (%)	1.7%	6.6%	7.7%	11.6%
Dividends (EUR)	1.30	1.30	1.30	1.30
Div yield (%)	2.9%	2.9%	2.9%	2.9%
EV/Sales	1.4x	1.5x	1.4x	1.3x
EV/EBITDA	7.0x	7.8x	6.7x	5.5x
EV/EBIT	12.1x	14.0x	11.0x	8.3x



Uncertainties regarding LH asset disposals in India

Fair Value CHF60 (+34%)

SELL

In order to comply with the Indian anti-trust entity CCI's demands, LH had signed last August an agreement with a local company Birla to sell some assets in India, mostly two plants in the East with a 5.2m tonnes of cement capacity, for an EV of CHF750m. Unfortunately, due to legal changes, the press reports Birla had some difficulties in securing the mining rights, which can't be simply be transferred anymore, but have to be attributed by auction. Still, according to the press, LH might sell its whole Lafarge Indian subsidiary, representing 11mt of cement capacities, with the mining rights directly included. It has not been officially confirmed though, but the new CCI chairman recently said an "alternative proposal" was "on the table", but no additional details were given. In any case, several potential bidders have been mentioned by the press, included CRH. LH would in any case remain a strong player in the country, with 62mt of capacity, although we can't see how "merger" synergies can be generated in the country in a scenario where all the Lafarge assets are disposed of.

In August 2015, LH signed an agreement with Birla Corporation in order to divest some assets located in the eastern part of the country and to comply with the Competition Commission of India (CCI)'s requests. EV was INR50bn or CHF750m for 5.15m tonnes of capacity, for mainly one cement plant and one grinding station. LafargeHolcim's combined capacity in India was 73 mt: 62mt from Holcim and 11mt from Lafarge. The initial plan was to retain 68mt after the Birla deal. Unfortunately, the Indian government amended the Mining Act a bit later. With the new policy, mining rights have to be won at auction and can't be simply transferred. And, according to the press since early January, Birla has faced some difficulties in securing the acquisition of the limestone reserves rights, while it was a condition of the deal with LH, as limestone access is essential for a cement plant. One of the solutions suggested by the press would be for LafargeHolcim to directly sell the Lafarge India company as a whole: all assets (plants, brands, mining rights...) included. In that case, limestone reserve rights do not have to be transferred but would stay within the same entity.

Whether LH sells the entire Lafarge India business or not, the Indian CCI new chairman has recently (6 January, CNBC) confirmed that LH has come back with an "alternative proposal", but he wasn't more specific. In any case, some potential buyers for the 11mt have been mentioned by the press, including CRH (BUY, FV EUR30). The EV of the deal is likely to be close to CHF1.5bn, if based on the same EV/tonnes ratio.

We have contacted LafargeHolcim. It admits the process has been delayed but didn't disclosed much details. However, it expects a decision from the CCI in the next couple of weeks. We have contacted CRH as well but it doesn't comment on speculation.

ANALYSIS

- As far as we understand, we will ignore today what might be the new proposal of LafargeHolcim until we get further details. However, in any case, the current issue underlines how India can be a complex, hard-to-predict country.
- If LH is forced to sell all Lafarge assets in India, then we can't see how "merger" synergies can be generated within India. Nevertheless, LH would in any case remain a strong player in the country, the leader with 62mt of capacity, with only 10% in the South, where utilisation rates are the lowest at c.60%. As a reminder, as a whole, LH got c.375mt of capacity and the first exposure is India.
- CRH has invested in 2015 EUR6.5bn in the LH assets and EUR1.2bn in CRLaurence and the
 leverage is likely to stand above 3x by the end of 2015 (we have 3.3x) and the target is less than
 2.5x at end 2016. Investing EUR1.4bn in a new asset is likely to postpone this objective. Besides,
 integrated various assets from LH will take time and energy from the management.


VALUATION

 CHF60 FV derived from the historical multiples application to our 2017e EBITDA, discounted back. Current EV/EBITDA stands at 6.7x 2017e, below c7.5x historical average or European sector ratio.


NEXT CATALYSTS

FY results on 17 March 2016


Key metrics



Sources: LafargeHolcim, Bryan, Garnier & co



Sources: LafargeHolcim, Bryan, Garnier & co



Sources: LafargeHolcim, Bryan, Garnier & co

Valuation multiples

BG multiples	Price*	Mk.		PE			EV/EBIT		Div.
x	11/01/16	000 2	2015e	2016e	2017e	2015e	2016e	2017e	2015e
LafargeHolcim (CHF)	44.84	27 214	21.7	13.7	9.8	7.8	6.7	5.5	2.9%
Vicat	51.18	2 298	16.1	13.2	10.0	7.7	7.0	5.7	2.9%
CRH	24.74	20 364	33.4	17.5	13.7	11.9	8.8	7.5	2.5%
HeidelbergCement	69.00	12 966	18.1	15.0	9.8	8.4	7.3	5.9	1.6%
Saint-Gobain	36.15	20 275	16.6	13.4	10.8	7.5	6.4	5.6	3.4%
Vinci	58.09	34 183	17.8	15.9	14.4	8.3	7.5	6.8	3.0%
Eiffage	57.15	5 454	17.6	15.2	12.7	9.2	8.9	8.5	2.1%
Cement average			23.7	14.8	11.2	9.1	7.5	6.2	2.8%
Building Materials average			22.3	14.9	10.8	9.0	7.2	6.2	2.5%

* in EUR, except LafargeHolcim Source : Bryan Garnier & Co. ests. Click here to download document



Analyst : Eric Lemarié 33(0) 1.70.36.57.17 elemarie@bryangarnier.com

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY

Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

NEUTRAL

Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

SELL

Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 58.5%

NEUTRAL ratings 32.3%

SELL ratings 9.2%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with th Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.		No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudential et de	2	FINMA	
(FCA)	resolution (ACPR)			

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report. Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.